Premium
Identification of SART3‐derived peptides capable of inducing HLA‐A2‐restricted and tumor‐specific CTLs in cancer patients with different HLA‐A2 subtypes
Author(s) -
Ito Masaaki,
Shichijo Shigeki,
Miyagi Yoshiaki,
Kobayashi Terutada,
Tsuda Naotake,
Yamada Akira,
Saito Norio,
Itoh Kyogo
Publication year - 2000
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/1097-0215(20001115)88:4<633::aid-ijc18>3.0.co;2-n
Subject(s) - human leukocyte antigen , epitope , ctl* , biology , complementary dna , cancer , transfection , immunology , immunotherapy , antigen , cancer immunotherapy , peripheral blood mononuclear cell , cancer research , cytotoxic t cell , microbiology and biotechnology , gene , immune system , cd8 , genetics , in vitro
We recently identified the SART3 antigen encoding shared tumor epitopes recognized by HLA‐A2402‐restricted and tumor‐specific CTLs. Our study investigated whether the SART3 antigen encodes peptides recognized by the HLA‐A2‐restricted CTLs. The HLA‐A2‐restricted and tumor‐specific CTL line recognized COS‐7 cells co‐transfected with the SART3 gene and either HLA‐A0201, ‐A0206 or ‐A0207 cDNA but not those co‐transfected with the SART3 gene and HLA‐A2402 or ‐A2601 cDNA. The 2 SART3 peptides at positions 302 to 310 and 309 to 317 possessed the ability to induce HLA‐A2‐restricted and tumor‐specific CTLs from peripheral blood mononuclear cells of cancer patients with various histological types and different HLA‐A2 subtypes. Therefore, these 2 peptides could be useful for specific immunotherapy of a relatively large number of HLA‐A2 + cancer patients. Int. J. Cancer 88:633–639, 2000. © 2000 Wiley‐Liss, Inc.